Frazier Life Sciences Management L.P. trimmed its position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 24.5% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,065,334 shares of the company’s stock after selling 344,859 shares during the quarter. Frazier Life Sciences Management L.P.’s holdings in Oric Pharmaceuticals were worth $10,813,000 at […]

Frazier Life Sciences Management L.P. decreased its position in Vaxcyte, Inc. (NASDAQ:PCVX – Free Report) by 12.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 474,405 shares of the company’s stock after selling 65,000 shares during the quarter. Frazier Life […]

Frazier Life Sciences Management L.P. grew its holdings in Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report) by 363.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,424,725 shares of the company’s stock after acquiring an additional 3,469,210 shares during the quarter. Lexeo Therapeutics accounts […]

Frazier Life Sciences Management L.P. grew its position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE – Free Report) by 10.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,567,275 shares of the company’s stock after purchasing an additional […]

Frazier Life Sciences Management L.P. acquired a new stake in Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 5,100,000 shares of the company’s stock, valued at approximately $31,926,000. Aura Biosciences accounts for 1.3% of Frazier Life Sciences Management […]